Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Post-ASH 2022 Multiple Myeloma Highlights

17 January 2023 | Virtual Meeting

Post-ASH 2022 Multiple Myeloma Highlights

17 January 2023 | Virtual Meeting

Expert-led presentations & discussions on key abstracts in multiple myeloma from ASH 2022

The Post-ASH 2022 Multiple Myeloma Highlights Virtual Workshop took place on 18 January, and featured a series of short presentations on selected abstracts from the 64th ASH Annual Meeting presented by experts with interactive panel discussions after each session. 

Newly diagnosed multiple myeloma Bispecific monoclonal antibodies Smoldering multiple myeloma CAR-T therapy Challenging settings in multiple myeloma

Session 1: Newly diagnosed multiple myeloma

Francesco Maura
Risk stratification in NDMM & genomic determinants of resistance
Francesco Maura Sylvester Comprehensive Cancer Center, Miami, FL, United States
Martin Kaiser
Updates from the UK OPTIMUM/Muk Nine trial
Martin Kaiser The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
Katja Weisel
Isa-KRd in patients with HR-NDMM: analysis of the GMMG-CONCEPT trial
Katja Weisel University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Panel discussion

Session 2: Bispecific monoclonal antibodies

Ajai Chari
Results from MonumenTAL-1: Talquetamab for R/R myeloma
Ajai Chari Mount Sinai Medical Center, New York City, NY, United States
Noopur Raje
Elranatamab for patients with R/R myeloma
Noopur Raje Massachusetts General Hospital, Boston, MA, United States
Emma Searle
Teclistamab + subcutaneous daratumumab & lenalidomide
Emma Searle The Christie NHS Foundation Trust, Manchester, United Kingdom
Carmelo Carlo-Stella
Updated results from a study of forimtamig
Carmelo Carlo-Stella Humanitas University, Milan, Italy
Panel discussion
Sandy Wong
Alnuctamab in patients with R/R multiple myeloma
Sandy Wong University of California San Francisco, San Francisco, CA, United States
Peter Voorhees
A study of Abbv-383 as monotherapy in patients with R/R myeloma
Peter Voorhees Levine Cancer Institute, Atrium Health, Charlotte, NC, United States
Alexander Lesokhin
Fixed-duration cevostamab therapy in patients with R/R myeloma
Alexander Lesokhin Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Panel discussion

Session 3: Smoldering multiple myeloma

Shaji Kumar
Results from the ASCENT trial: Dara-KRd in high-risk smoldering myeloma
Shaji Kumar Mayo Clinic, Rochester, MN, United States
Maria-Victoria Mateos
Results from the randomized Phase III ITHACA trial
Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
Maria-Victoria Mateos
CurativE StrAtegy (GEM-CESAR) for high-risk smoldering myeloma
Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
Panel discussion

Session 4: CAR-T Cell Therapy

Luciano Costa
Phase I study of CC-95266 in patients with R/R myeloma
Luciano Costa UAB School of Medicine, Birmingham, AL, United States
Luciano Costa
Results from the first Phase I study of CC-98633 in patients with R/R myeloma
Luciano Costa UAB School of Medicine, Birmingham, AL, United States
Bruno Paiva
Early and sustained uMRD after ide-cel in patients enrolled in the KarMMa trial
Bruno Paiva University of Navarra, Pamplona, Spain
Paul Richardson
Preliminary results from the CC-92480-MM-001 trial
Paul Richardson Dana-Farber Cancer Institute, Boston, MA, United States
Panel discussion

Session 5: Challenging settings in multiple myeloma

Laura Notarfranchi
Ultra-sensitive assessment of MRD in peripheral blood of myeloma patients
Laura Notarfranchi University of Parma, Parma, Italy
Noemí Puig
Clinical impact of NGF vs QIP-MS to assess MRD in NDMM patients
Noemí Puig University Hospital Salamanca, Salamanca, Spain
Panel discussion

The continued success of the post-ASH meetings is in no small part due to the ongoing funding of supporters, allowing unique opportunities for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes.
For more information about supporting future meetings and activities, please contact us here.

For the latest updates in myeloma, explore the Multiple Myeloma Channel

The content of VJHemOnc is intended for healthcare professionals